The effect of a therapeutic dendritic cell-based cancer vaccination depends on the blockage of CTLA-4 signaling

Cancer Letters

Volumn 231, Issue 2, 2006, Pages 247-256

  Met, Özcan ^a   Wang, Mingjun ^a   Pedersen, Anders E ^a   Nissen, Mogens H ^a   Buus, Søren ^a   Claesson, Mogens H ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Cancer; CTLA 4; Dendritic cells; ELISPOT; Vaccine

Indexed keywords

CANCER VACCINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DENDRITIC CELL VACCINE; GAMMA INTERFERON; INTERLEUKIN 2; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CTLA 4; SERYLISOLEUCYLISOLEUCYLASPARAGINYLPHENYLALANYLGLUTAMYLLYSYLLEUCINAMIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CARCINOGENESIS; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFECT; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; INOCULATION; LYMPHOMA; LYMPHOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSGENE; TUMOR CELL; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR REJECTION; VACCINATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION; BONE MARROW; CANCER VACCINES; DENDRITIC CELLS; DRUG THERAPY, COMBINATION; EGG PROTEINS; EPITOPES; FEMALE; H-2 ANTIGENS; LYMPHOMA; MICE; MICE, INBRED C57BL; OVALBUMIN; PEPTIDE FRAGMENTS; SIGNAL TRANSDUCTION; SPLEEN; T-LYMPHOCYTES, CYTOTOXIC; THYMOMA; TRANSGENES; VACCINATION;

ANIMALIA;

EID: 29844436043     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2005.02.005     Document Type: Article

References (32)

1. A.A. Hurwitz, B.A. Foster, E.D. Kwon, T. Truong, E.M. Choi, and N.M. Greenberg Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade Cancer Res. 60 2000 2444 2448
2. N. Shibagaki, and M.C. Udey Dendritic cells transduced with protein antigens induce cytotoxic lymphocytes and elicit antitumor immunity J. Immunol. 168 2002 2393 2401
3. A. van Elsas, A.A. Hurwitz, and J.P. Allison Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation J. Exp. Med. 190 1999 355 366
4. A. van Elsas, R.P. Sutmuller, A.A. Hurwitz, J. Ziskin, J. Villasenor, and J.P. Medema Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy J. Exp. Med. 194 2001 481 489
5. F.J. Hsu, and M. Komarovskaya CTLA4 blockade maximizes antitumor T-cell activation by dendritic cells presenting idiotype protein or opsonized anti-CD20 antibody-coated lymphoma cells J. Immunother. 25 2002 455 468
6. T.S. Kim, S.W. Chung, and S.Y. Hwang Augmentation of antitumor immunity by genetically engineered fibroblast cells to express both B7.1 and interleukin-7 Vaccine 18 2000 2886 2894
7. G.B. Lipford, M. Hoffman, H. Wagner, and K. Heeg Primary in vivo responses to ovalbumin. Probing the predictive value of the Kb binding motif J. Immunol. 150 1993 1212 1222
8. S. Demaria, N Kawashima, M. Devitt, J.P. Allison, and S.C. Formenti Combination of local radiation with CTLA4 blockade: a new approach to the immunotherapy of breast cancer Int. J. Radiat Oncol. Biol. Phys. 57 2003 S259
9. M.W. Moore, F.R. Carbone, and M.J. Bevan Introduction of soluble protein into the class I pathway of antigen processing and presentation Cell 54 1988 777 785
10. J.W. Kappler, B. Skidmore, J. White, and P. Marrack Antigen-inducible, H-2-restricted, interleukin-2-producing T cell hybridomas. Lack of independent antigen and H-2 recognition J. Exp. Med. 153 1981 1198 1214
11. K.L. Rock, L. Rothstein, and S. Gamble Generation of class I MHC-restricted T-T hybridomas J. Immunol. 145 1990 804 811
12. O. Met, S. Buus, and M.H. Claesson Peptide-loaded dendritic cells prime and activate MHC-class I-restricted T cells more efficiently than protein-loaded cross-presenting DC Cell Immunol. 222 2003 126 133
13. M.F. Krummel, and J.P. Allison CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation J. Exp. Med. 182 1995 459 465
14. E.N. Lalani, F. Berdichevsky, M. Boshell, M. Shearer, D. Wilson, and H. Stauss Expression of the gene coding for a human mucin in mouse mammary tumor cells can affect their tumorigenicity J. Biol. Chem. 266 1991 15420 15426
15. M.J. Wang, M.H. Nissen, S. Buus, C. Ropke, and M.H. Claesson Comparison of CTL reactivity in the spleen and draining lymph nodes after immunization with peptides pulsed on dendritic cells or mixed with Freund's incomplete adjuvant Immunol. Lett. 90 2003 13 18
16. L. Forchhammer, M. Thorn, O. Met, M. Gad, M.S. Weidner, and M.H. Claesson Immunobiological effects of glucosamine in vitro Scand. J. Immunol. 58 2003 404 411
17. A. Takeda, S. Homma, T. Okamoto, D. Kufe, and T. Ohno Immature dendritic cell/tumor cell fusions induce potent antitumour immunity Eur. J. Clin. Invest. 33 2003 897 904
18. J. Gong, D. Chen, M. Kashiwaba, and D. Kufe Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells Nat. Med. 3 1997 558 561
19. X. Cao, W. Zhang, J. Wang, M. Zhang, X. Huang, and H. Hamada Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells Immunology 97 1999 616 625
20. Y. Tanaka, S. Koido, D. Chen, S.J. Gendler, D. Kufe, and J. Gong Vaccination with allogeneic dendritic cells fused to carcinoma cells induces antitumor immunity in MUC1 transgenic mice Clin. Immunol. 101 2001 192 200
21. A. Kugler, G. Stuhler, P. Walden, G. Zoller, A. Zobywalski, and P. Brossart Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids Nat. Med. 6 2000 332 336
22. F.O. Nestle, S. Alijagic, M. Gilliet, Y. Sun, S. Grabbe, and R. Dummer Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells Nat. Med. 4 1998 328 332
23. N. Okada, M. Sujino, Y. Hagiwara, A. Tada, Y. Tamura, and K. Mori Administration route-dependent vaccine efficiency of murine dendritic cells pulsed with antigens Br. J. Cancer 84 2001 1564 1570
24. A. Porgador, D. Snyder, and E. Gilboa Induction of antitumor immunity using bone marrow-generated dendritic cells J. Immunol. 156 1996 2918 2926
25. K. el Shami, B. Tirosh, E. Bar-Haim, L. Carmon, E. Vadai, and M. Fridkin MHC class I-restricted epitope spreading in the context of tumor rejection following vaccination with a single immunodominant CTL epitope Eur. J. Immunol. 29 1999 3295 3301
26. D.R. Leach, M.F. Krummel, and J.P. Allison Enhancement of antitumor immunity by CTLA-4 blockade Science 271 1996 1734 1736
27. F.M. Marincola, E.M. Jaffee, D.J. Hicklin, and S. Ferrone Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance Adv. Immunol. 74 2000 181 273
28. S. Ferrone, and F.M. Marincola Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance Immunol. Today 16 1995 487 494
29. P.G. Natali, A. Bigotti, M.R. Nicotra, M. Viora, D. Manfredi, and S. Ferrone Distribution of human Class I (HLA-A,B,C) histocompatibility antigens in normal and malignant tissues of nonlymphoid origin Cancer Res. 44 1984 4679 4687
30. P.J. Travers, J.L. Arklie, J. Trowsdale, R.A. Patillo, and W.F. Bodmer Lack of expression of HLA-ABC antigens in choriocarcinoma and other human tumor cell lines Natl Cancer Inst. Monogr. 60 1982 175 180
31. C. Kurts, J.F. Miller, R.M. Subramaniam, F.R. Carbone, and W.R. Heath Major histocompatibility complex class I-restricted cross-presentation is biased towards high dose antigens and those released during cellular destruction J. Exp. Med. 188 1998 409 414
32. J.G. Egen, M.S. Kuhns, and J.P. Allison CTLA-4: new insights into its biological function and use in tumor immunotherapy Nat. Immunol. 3 2002 611 618